Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Chemotherapy. Cross Cancer Institute, Alberta, Canada

Survival: 8.5 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Adriamycin
Country: Canada
City/State/Province: Alberta
Hospital: Cross Cancer Institute
Journal: Link
Date: 9/2006

Patients: This phase II trial involved 15 patients with advanced malignant melanoma. The median age was 62 years, ranging from 29-86. Most had received no prior therapy for metastatic disease, and 4 had received radiotherapy

Treatment: All patients were treated with the chemotherapy drug doxorubicin (Caelyx).

Toxicity: One patient had severe neutropenia and one had severe thrombocytopenia. The most common toxic side effects were fatigue, nausea, and anorexia.

Results: At the end of the study, 13 patients had died and two were alive, with a median survival time of 255 days (8.5 months). The authors conclude that this “study confirms the lack of clinical activity of doxorubicin in patients with advanced malignant melanoma”.

Correspondence: Dr. Michael Smylie

E-mail to a Friend Email Physician More Information